Pacer Advisors’s Zimmer Biomet ZBH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.26M | Sell |
14,682
-726,912
| -98% | -$63.7M | ﹤0.01% | 1203 |
|
|
2026
Q1 | $67.1M | Buy |
741,594
+43,841
| +6% | +$4.02M | 0.19% | 132 |
|
|
2025
Q4 | $62.7M | Buy |
697,753
+680,818
| +4,020% | +$64.6M | 0.16% | 143 |
|
|
2025
Q3 | $1.67M | Sell |
16,935
-844,530
| -98% | -$83.7M | ﹤0.01% | 1169 |
|
|
2025
Q2 | $78.6M | Buy |
861,465
+851,257
| +8,339% | +$82.3M | 0.2% | 110 |
|
|
2025
Q1 | $1.16M | Sell |
10,208
-5,717
| -36% | -$612K | ﹤0.01% | 1148 |
|
|
2024
Q4 | $1.68M | Sell |
15,925
-1,931
| -11% | -$207K | ﹤0.01% | 1094 |
|
|
2024
Q3 | $1.93M | Buy |
17,856
+266
| +2% | +$29K | ﹤0.01% | 1003 |
|
|
2024
Q2 | $1.91M | Buy |
17,590
+1,135
| +7% | +$134K | ﹤0.01% | 959 |
|
|
2024
Q1 | $2.17M | Sell |
16,455
-279
| -2% | -$34.9K | 0.01% | 821 |
|
|
2023
Q4 | $2.04M | Buy |
16,734
+109
| +0.7% | +$12.2K | 0.01% | 765 |
|
|
2023
Q3 | $1.87M | Buy |
16,625
+197
| +1% | +$25K | 0.01% | 628 |
|
|
2023
Q2 | $2.39M | Buy |
16,428
+3,638
| +28% | +$494K | 0.01% | 683 |
|
|
2023
Q1 | $1.65M | Buy |
12,790
+12,032
| +1,587% | +$1.51M | 0.01% | 756 |
|
|
2022
Q4 | $96.6K | Sell |
758
-4,895
| -87% | -$568K | ﹤0.01% | 2622 |
|
|
2022
Q3 | $591K | Buy |
5,653
+78
| +1% | +$8.56K | ﹤0.01% | 693 |
|
|
2022
Q2 | $586K | Sell |
5,575
-5,184
| -48% | -$615K | ﹤0.01% | 658 |
|
|
2022
Q1 | $1.38M | Sell |
10,759
-372
| -3% | -$44.8K | 0.01% | 758 |
|
|
2021
Q4 | $1.37M | Sell |
11,131
-5,237
| -32% | -$685K | 0.01% | 1016 |
|
|
2021
Q3 | $2.33M | Buy |
16,368
+1,147
| +8% | +$169K | 0.03% | 642 |
|
|
2021
Q2 | $2.38M | Buy |
15,221
+3,270
| +27% | +$530K | 0.03% | 574 |
|
|
2021
Q1 | $1.86M | Sell |
11,951
-1,235
| -9% | -$191K | 0.03% | 535 |
|
|
2020
Q4 | $1.97M | Sell |
13,186
-5,507
| -29% | -$778K | 0.04% | 445 |
|
|
2020
Q3 | $2.47M | Sell |
18,693
-3,190
| -15% | -$417K | 0.05% | 340 |
|
|
2020
Q2 | $2.54M | Buy |
+21,883
| New | +$2.52M | 0.05% | 276 |
|
|
2020
Q1 | – | Sell |
-23,656
| Closed | -$3.44M | – | 1153 |
|
|
2019
Q4 | $3.44M | Sell |
23,656
-461
| -2% | -$63.6K | 0.16% | 118 |
|
|
2019
Q3 | $3.21M | Buy |
24,117
+2,490
| +12% | +$322K | 0.07% | 294 |
|
|
2019
Q2 | $2.47M | Buy |
21,627
+2,814
| +15% | +$330K | 0.06% | 377 |
|
|
2019
Q1 | $2.33M | Buy |
+18,813
| New | +$2.14M | 0.06% | 266 |
|
|
2018
Q4 | – | Sell |
-11,032
| Closed | -$1.41M | – | 1068 |
|
|
2018
Q3 | $1.41M | Buy |
11,032
+1,541
| +16% | +$183K | 0.05% | 482 |
|
|
2018
Q2 | $1.03M | Buy |
9,491
+1,660
| +21% | +$181K | 0.05% | 607 |
|
|
2018
Q1 | $829K | Buy |
7,831
+921
| +13% | +$107K | 0.05% | 555 |
|
|
2017
Q4 | $810K | Buy |
6,910
+1,677
| +32% | +$190K | 0.06% | 505 |
|
|
2017
Q3 | $595K | Buy |
5,233
+497
| +10% | +$57.4K | 0.05% | 578 |
|
|
2017
Q2 | $590K | Buy |
4,736
+362
| +8% | +$42.9K | 0.06% | 502 |
|
|
2017
Q1 | $519K | Buy |
4,374
+136
| +3% | +$15.4K | 0.06% | 465 |
|
|
2016
Q4 | $425K | Sell |
4,238
-25
| -0.6% | -$2.68K | 0.06% | 484 |
|
|
2016
Q3 | $538K | Sell |
4,263
-25
| -0.6% | -$3.09K | 0.08% | 331 |
|
|
2016
Q2 | $501K | Buy |
4,288
+815
| +23% | +$92.2K | 0.08% | 331 |
|
|
2016
Q1 | $360K | Buy |
3,473
+355
| +11% | +$34.3K | 0.08% | 258 |
|
|
2015
Q4 | $311K | Buy |
+3,118
| New | +$305K | 0.07% | 281 |
|
Other funds holding ZBH
Pacer Advisors's ZBH Position: Q2 2026 in Review
Pacer Advisors reduced its Zimmer Biomet (ZBH) stake by 98% in Q2 2026, selling an estimated $63.7M and leaving 14,682 shares worth $1.26M. The position accounts for ﹤0.01% of the portfolio, ranked #1203.
Pacer Advisors first reported a position in ZBH in Q4 2015 and has held it in 41 quarters since. The position peaked at $78.6M in Q2 2025. 906 funds tracked by Wall St. Rank hold ZBH as of Q2 2026.
- Pacer Advisors held 14,682 shares of Zimmer Biomet worth $1.26M as of Q2 2026.
- Pacer Advisors sold 726,912 Zimmer Biomet shares in Q2 2026, an estimated $63.7M.
- Zimmer Biomet made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #1203 holding.
- Pacer Advisors first reported a position in Zimmer Biomet in Q4 2015 and has held it in 41 quarters since.
- Pacer Advisors's Zimmer Biomet position peaked at $78.6M in Q2 2025.
- 906 funds tracked by Wall St. Rank held Zimmer Biomet as of Q2 2026.
Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.